Q-omics provides the consensus-scored KRT9 profile across patient tissues and cancer cell-line models. KRT9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KRT9 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, KRT9 RNA expression shows 10,422 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUAD, HNSC, and ESCA as cancer lineages where KRT9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT9 survival associations across molecular data types. KRT9 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT9 RNA expression–survival associations across cancer types. High KRT9 expression shows unfavorable associations in LUAD, MESO, KICH, PAAD and KIRP, but favorable associations in SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KRT9 RNA expression.
This table summarizes KRT9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT9 shows lower tumor expression in COAD, BRCA and READ and higher tumor expression in HNSC, LUSC and BLCA. The HNSC box plot shows higher KRT9 RNA expression in tumor versus normal tissue (log2 FC = +1.193, t-test p < 0.001).
This table shows molecular features associated with KRT9 in patient tissues and cancer cell lines. In patient samples, KRT9 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
